{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/prov/97376405"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/410135057" ] } },

    { "id" : "http://webisa.webdatacommons.org/410135057"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "In addition to naproxcinod, NicOx's pipeline includes several nitric oxide- donating NCEs, which are in development internally and with partners, including Merck & Co., Inc., for the treatment of widespread eye diseases, cardiometabolic diseases, hypertension and dermatological disease." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biospace.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/29553199"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/410135057" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/207634621"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/410135057" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/226606308"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/410135057"] } } }
